ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find attached herewith the intimation received from our RTA.18-06-2024
18-06-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alembic Pharmaceuticals receives USFDA Final Approval for Dabigatran Etexilate Capsules, 75 mg and 150 mg and Tentative approval for Dabigatran Etexilate Capsules, 110 mg18-06-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
The Company has received an order from the Office of the Commissioner of Customs under applicable provisions of the Customs Act, 1962 and 3 orders from Office of Director of Prohibition and Excise Department under applicable provisions of the Gujarat Prohibition Act, 1949.17-06-2024
Alembic Pharma gets USFDA Final Approval for Icatibant Injection
The USDFA approval is for Icatibant Injection of strengths of30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe17-06-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
The Company has received the USFDA Final approval for Icatibant Injection 30 mg/3mL (10 mg/mL) Single dose prefilled syringe. This is the first peptide product approval from the USFDA received by the Company.17-06-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Newspaper Advertisement07-06-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Change in Senior Management Personnel07-06-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find attached herewith the intimation dated 5th June 2024 received from our RTA.05-06-2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Resignation of Senior Management Personnel.31-05-2024
Alembic Pharma Receives USFDA Approval To Market Heart Failure Drug
Alembic Pharma secures USFDA approval to market heart failure drug, equivalent to Novartis's Entresto tablets.30-05-2024